Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals' board granted inducement stock options on 58,663 shares and RSUs covering 49,687 shares to 18 new hires and new Chief Medical Officer Rob Myers under its 2020 Inducement Plan. Options carry an $86.01 exercise price, equal to the October 9, 2026 close, vesting over four years; RSUs vest over three years.
Key figures
- Grant date
- 2026-10-09
- New employees granted
- 18
- Option exercise price
- 86.01
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.